| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1006173053 |
| P356 | DOI | 10.1038/SJ.GT.3301829 |
| P698 | PubMed publication ID | 12424610 |
| P5875 | ResearchGate publication ID | 10658745 |
| P2093 | author name string | Chamberlain JS | |
| Li J | |||
| Yamamoto H | |||
| Takeda S | |||
| Sakamoto M | |||
| Yuasa K | |||
| Xiao X | |||
| Miyagoe-Suzuki Y | |||
| Tanouchi A | |||
| P2860 | cites work | Tissue distribution of the DEC-205 protein that is detected by the monoclonal antibody NLDC-145. II. Expression in situ in lymphoid and nonlymphoid tissues | Q72256256 |
| In vivo targeted repair of a point mutation in the canine dystrophin gene by a chimeric RNA/DNA oligonucleotide | Q73844338 | ||
| rAAV vector-mediated sarcogylcan gene transfer in a hamster model for limb girdle muscular dystrophy | Q28144597 | ||
| Muscle-specific promoters may be necessary for adeno-associated virus-mediated gene transfer in the treatment of muscular dystrophies. | Q31934596 | ||
| Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers | Q33782809 | ||
| CD40 ligand-dependent activation of cytotoxic T lymphocytes by adeno-associated virus vectors in vivo: role of immature dendritic cells | Q33810726 | ||
| Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice | Q33871190 | ||
| Very mild muscular dystrophy associated with the deletion of 46% of dystrophin | Q34371637 | ||
| Modification of splicing in the dystrophin gene in cultured Mdx muscle cells by antisense oligoribonucleotides | Q34470860 | ||
| Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model | Q35573761 | ||
| Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector | Q35872651 | ||
| Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein | Q35943644 | ||
| Animal models for muscular dystrophy show different patterns of sarcolemmal disruption. | Q36273863 | ||
| E-box sites and a proximal regulatory region of the muscle creatine kinase gene differentially regulate expression in diverse skeletal muscles and cardiac muscle of transgenic mice | Q36562319 | ||
| Rescue of dystrophin expression in mdx mouse muscle by RNA/DNA oligonucleotides | Q36973971 | ||
| A new adenoviral vector: Replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and beta-galactosidase | Q37551841 | ||
| The immunobiology of muscle | Q40693166 | ||
| Corticosteroid therapy in Duchenne muscular dystrophy | Q40804832 | ||
| Rescue of skeletal muscles of gamma-sarcoglycan-deficient mice with adeno-associated virus-mediated gene transfer. | Q40863195 | ||
| The fate of individual myoblasts after transplantation into muscles of DMD patients | Q40883106 | ||
| Effective restoration of dystrophin-associated proteins in vivo by adenovirus-mediated transfer of truncated dystrophin cDNAs | Q41048543 | ||
| Efficient adenovirus-mediated transfer of a human minidystrophin gene to skeletal muscle of mdx mice | Q41572953 | ||
| Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain | Q42280576 | ||
| Stable restoration of the sarcoglycan complex in dystrophic muscle perfused with histamine and a recombinant adeno-associated viral vector | Q43783192 | ||
| Effective adenovirus-mediated gene expression in adult murine skeletal muscle | Q43966131 | ||
| Recombinant adeno-associated virus for muscle directed gene therapy | Q45764433 | ||
| DNA from both high-capacity and first-generation adenoviral vectors remains intact in skeletal muscle. | Q45856685 | ||
| Immune evasion by muscle-specific gene expression in dystrophic muscle | Q45881906 | ||
| Dystrophin expression in muscles of mdx mice after adenovirus-mediated in vivo gene transfer | Q57043072 | ||
| Amelioration of the dystrophic phenotype of mdx mice using a truncated utrophin transgene | Q59053234 | ||
| Human dystrophin expression in mdx mice after intramuscular injection of DNA constructs | Q59080986 | ||
| Macrophages and dendritic cells in normal and regenerating murine skeletal muscle | Q59400553 | ||
| Immune response to adenovirus-delivered antigens upregulates utrophin and results in mitigation of muscle pathology in mdx mice | Q64380856 | ||
| P433 | issue | 23 | |
| P921 | main subject | vector-borne disease | Q2083837 |
| P304 | page(s) | 1576-1588 | |
| P577 | publication date | 2002-12-01 | |
| P1433 | published in | Gene Therapy | Q15763095 |
| P1476 | title | Adeno-associated virus vector-mediated gene transfer into dystrophin-deficient skeletal muscles evokes enhanced immune response against the transgene product | |
| P478 | volume | 9 |
| Q45007200 | A facile nonviral method for delivering genes and siRNAs to skeletal muscle of mammalian limbs |
| Q35083651 | A multidisciplinary evaluation of the effectiveness of cyclosporine a in dystrophic mdx mice. |
| Q36226779 | A novel gene expression system: non-viral gene transfer for hemophilia as model systems |
| Q45127732 | AAV vector-mediated microdystrophin expression in a relatively small percentage of mdx myofibers improved the mdx phenotype |
| Q37687423 | AAV-directed muscular dystrophy gene therapy |
| Q28283362 | AAV-mediated overexpression of human α7 integrin leads to histological and functional improvement in dystrophic mice |
| Q34267400 | Advances in Duchenne muscular dystrophy gene therapy |
| Q36848984 | Antibody formation and mannose-6-phosphate receptor expression impact the efficacy of muscle-specific transgene expression in murine Pompe disease. |
| Q40667121 | Antisense pre-treatment increases gene therapy efficacy in dystrophic muscles. |
| Q91340859 | CRISPR-Induced Deletion with SaCas9 Restores Dystrophin Expression in Dystrophic Models In Vitro and In Vivo |
| Q36484108 | Complement is an essential component of the immune response to adeno-associated virus vectors |
| Q42437569 | Construction and analysis of compact muscle-specific promoters for AAV vectors |
| Q45457148 | Correction of glycogen storage disease type II by an adeno-associated virus vector containing a muscle-specific promoter |
| Q37161996 | Correction of multiple striated muscles in murine Pompe disease through adeno-associated virus-mediated gene therapy |
| Q37277411 | Current Challenges and Future Directions in Recombinant AAV-Mediated Gene Therapy of Duchenne Muscular Dystrophy |
| Q40181522 | Design of tissue-specific regulatory cassettes for high-level rAAV-mediated expression in skeletal and cardiac muscle |
| Q43427810 | Direct comparison of four adeno-associated virus serotypes in mediating the production of antiangiogenic proteins in mouse muscle |
| Q92547654 | Dual muscle-liver transduction imposes immune tolerance for muscle transgene engraftment despite preexisting immunity |
| Q36085192 | Dysferlin and animal models for dysferlinopathy |
| Q33313653 | Dystrophin deficiency in canine X-linked muscular dystrophy in Japan (CXMDJ) alters myosin heavy chain expression profiles in the diaphragm more markedly than in the tibialis cranialis muscle |
| Q36960845 | Emerging strategies for cell and gene therapy of the muscular dystrophies |
| Q45872960 | Endogenous microRNA can be broadly exploited to regulate transgene expression according to tissue, lineage and differentiation state |
| Q59353297 | Engineered DNA plasmid reduces immunity to dystrophin while improving muscle force in a model of gene therapy of Duchenne dystrophy |
| Q45259698 | Evasion of immune responses to introduced human acid alpha-glucosidase by liver-restricted expression in glycogen storage disease type II. |
| Q40576976 | Expression of dystrophin driven by the 1.35-kb MCK promoter ameliorates muscular dystrophy in fast, but not in slow muscles of transgenic mdx mice |
| Q35062311 | Fukutin is prerequisite to ameliorate muscular dystrophic phenotype by myofiber-selective LARGE expression |
| Q45863474 | Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse |
| Q34180144 | Gene Therapy for Muscular Dystrophies: Progress and Challenges |
| Q34566454 | Gene replacement therapies for duchenne muscular dystrophy using adeno-associated viral vectors |
| Q35184730 | Gene therapy for muscular dystrophy - a review of promising progress |
| Q36345325 | Gene therapy strategies for Duchenne muscular dystrophy utilizing recombinant adeno-associated virus vectors. |
| Q45007194 | HLA-A*0201-restricted cytolytic responses to the rtTA transactivator dominant and cryptic epitopes compromise transgene expression induced by the tetracycline on system. |
| Q37018636 | How not to be seen: immune-evasion strategies in gene therapy. |
| Q41668084 | Human α7 Integrin Gene (ITGA7) Delivered by Adeno-Associated Virus Extends Survival of Severely Affected Dystrophin/Utrophin-Deficient Mice |
| Q45864503 | Identification of an HLA-A*0201-restricted epitopic peptide from human dystrophin: application in duchenne muscular dystrophy gene therapy. |
| Q35131229 | Immune responses to adeno-associated virus and its recombinant vectors |
| Q45868920 | Improvement of cardiac fibrosis in dystrophic mice by rAAV9-mediated microdystrophin transduction. |
| Q45857485 | In vitro characterization and in vivo expression of human very-long chain acyl-CoA dehydrogenase. |
| Q37472002 | In vivo delivery of a microRNA-regulated transgene induces antigen-specific regulatory T cells and promotes immunologic tolerance |
| Q33736192 | Influence of immune responses in gene/stem cell therapies for muscular dystrophies |
| Q45868913 | Injection of a recombinant AAV serotype 2 into canine skeletal muscles evokes strong immune responses against transgene products |
| Q27317882 | Intra-amniotic rAAV-mediated microdystrophin gene transfer improves canine X-linked muscular dystrophy and may induce immune tolerance |
| Q40117829 | Intradermal Immunization with rAAV1 Vector Induces Robust Memory CD8(+) T Cell Responses Independently of Transgene Expression in DCs. |
| Q44861538 | Mir-142-3p target sequences reduce transgene-directed immunogenicity following intramuscular adeno-associated virus 1 vector-mediated gene delivery |
| Q92940638 | Muscle-Directed Delivery of an AAV1 Vector Leads to Capsid-Specific T Cell Exhaustion in Nonhuman Primates and Humans |
| Q37352442 | Muscular dystrophy therapy by nonautologous mesenchymal stem cells: muscle regeneration without immunosuppression and inflammation |
| Q37743813 | Novel adeno-associated virus vector vaccine restricts replication of simian immunodeficiency virus in macaques |
| Q35172284 | Novel therapies for Duchenne muscular dystrophy |
| Q37562066 | Plasmapheresis eliminates the negative impact of AAV antibodies on microdystrophin gene expression following vascular delivery. |
| Q39500834 | Recombinant AAV serotype and capsid mutant comparison for pulmonary gene transfer of alpha-1-antitrypsin using invasive and noninvasive delivery |
| Q35904461 | Recombinant adeno-associated viral (rAAV) vectors as therapeutic tools for Duchenne muscular dystrophy (DMD). |
| Q34984541 | Reversal of RNA missplicing and myotonia after muscleblind overexpression in a mouse poly(CUG) model for myotonic dystrophy |
| Q33847391 | Self-complementary AAV virus (scAAV) safe and long-term gene transfer in the trabecular meshwork of living rats and monkeys |
| Q45861904 | Soluble TNF-α receptor secretion from healthy or dystrophic mice after AAV6-mediated muscle gene transfer |
| Q80141652 | Sustained AAV-mediated dystrophin expression in a canine model of Duchenne muscular dystrophy with a brief course of immunosuppression |
| Q33715654 | Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles |
| Q34347199 | Systemic delivery of genes to striated muscles using adeno-associated viral vectors. |
| Q41844091 | Targeted Gene Addition of Microdystrophin in Mice Skeletal Muscle via Human Myoblast Transplantation |
| Q38539938 | The Skeletal Muscle Environment and Its Role in Immunity and Tolerance to AAV Vector-Mediated Gene Transfer |
| Q37455625 | Therapeutic advances in muscular dystrophy |
| Q34982869 | Therapeutic approaches to muscular dystrophy. |
| Q36549699 | Therapeutic restoration of dystrophin expression in Duchenne muscular dystrophy. |
| Q37134005 | Toward exascale production of recombinant adeno-associated virus for gene transfer applications |
| Q33713019 | Transduction efficiency and immune response associated with the administration of AAV8 vector into dog skeletal muscle |
| Q34517044 | Transduction of skeletal muscles with common reporter genes can promote muscle fiber degeneration and inflammation |
| Q33496681 | Transgene expression levels determine the immunogenicity of transduced hematopoietic grafts in partially myeloablated mice. |
| Q36448393 | Treatment of human disease by adeno-associated viral gene transfer |
| Q38746238 | Viral vectors for therapy of neurologic diseases |
Search more.